Clinical Trial: A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07185243) titled 'A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.' on Sept. 11.

Brief Summary: The purpose of this study is to evaluate the safety and primary efficacy of the combination therapy of recombinant human IL-21-expressing oncolytic vaccinia virus (hV01) and the PD-1 Inhibitor Tislelizumab in patients with advanced solid tumors.

Study Start Date: June 23

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: BIOLOGICAL: recombinant human IL-21-expressing oncolytic vaccinia virus injection

hV01 is a recombinant vaccinia virus with deletions of ...